Viral diseases

Viral diseases

by | Nov 25, 2020 | Clinical stage products, Non classé

Medesis Pharma is developing a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 – NanoManganese®). Preclinical trials have been carried out with the French Armed Forces Biomedical Research Institute (IRBA). (Study...
Nuclear radioprotection drug

Nuclear radioprotection drug

by | Jul 7, 2017 | Clinical stage products, In one

The objective of the radioprotection program is to develop a radiomitigation drug, administered in the minutes / hours following an overexposure to ionizing radiation. It will be used for the treatment of civilian and military personnel (dual technology) exposed...
AONYS® drug delivery technology

AONYS® drug delivery technology

by | Jun 13, 2017 | Clinical stage products

AONYS® is a mix of lipidic components that spontaneously assemble into a water-in-oil microemulsion. The active agent is solubilized in the aqueous phase of the microemulsion, within reverse micelles of 4 to 5 nm in diameter. AONYS® allows the administration of low...
Drug to treat neurodegenerative diseases

Drug to treat neurodegenerative diseases

by | Jun 13, 2017 | Clinical stage products

NanoLithium® (NP03) is a disease-modifying nano dose formulation of lithium citrate in an AONYS® reverse microemulsion. NP03 allows the delivery of lithium citrate to all tissues with a strong therapeutic efficacy at doses two orders of magnitude lower than those used...
Cesium decorporation

Cesium decorporation

by | Jun 13, 2017 | In one

Directly linked to 137Cs are numerous diseases not only limited to the increased prevalence of cancers (e.g. neurological diseases). Increases in premature births and birth malformations have been observed over a very wide geographical area. Children are particularly...